209 related articles for article (PubMed ID: 28346406)
1. Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase.
Stanford SM; Aleshin AE; Zhang V; Ardecky RJ; Hedrick MP; Zou J; Ganji SR; Bliss MR; Yamamoto F; Bobkov AA; Kiselar J; Liu Y; Cadwell GW; Khare S; Yu J; Barquilla A; Chung TDY; Mustelin T; Schenk S; Bankston LA; Liddington RC; Pinkerton AB; Bottini N
Nat Chem Biol; 2017 Jun; 13(6):624-632. PubMed ID: 28346406
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.
Stanford SM; Diaz MA; Ardecky RJ; Zou J; Roosild T; Holmes ZJ; Nguyen TP; Hedrick MP; Rodiles S; Guan A; Grotegut S; Santelli E; Chung TDY; Jackson MR; Bottini N; Pinkerton AB
J Med Chem; 2021 May; 64(9):5645-5653. PubMed ID: 33914534
[TBL] [Abstract][Full Text] [Related]
3. Loss of low-molecular-weight protein tyrosine phosphatase shows limited improvement in glucose tolerance but causes mild cardiac hypertrophy in mice.
Jensen-Cody S; Coyne ES; Ding X; Sebin A; Vogel J; Goldstein J; Rosahl TW; Zhou HH; Jacobs H; Champy MF; About GB; Talukdar S; Zhou Y
Am J Physiol Endocrinol Metab; 2022 Jun; 322(6):E517-E527. PubMed ID: 35403438
[TBL] [Abstract][Full Text] [Related]
4. In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
Rao GS; Ramachandran MV; Bajaj JS
J Biomol Struct Dyn; 2006 Feb; 23(4):377-84. PubMed ID: 16363874
[TBL] [Abstract][Full Text] [Related]
5. Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
Liu G; Trevillyan JM
Curr Opin Investig Drugs; 2002 Nov; 3(11):1608-16. PubMed ID: 12476961
[TBL] [Abstract][Full Text] [Related]
6. Protein tyrosine phosphatase 1B inhibitors for diabetes.
Johnson TO; Ermolieff J; Jirousek MR
Nat Rev Drug Discov; 2002 Sep; 1(9):696-709. PubMed ID: 12209150
[TBL] [Abstract][Full Text] [Related]
7. Virtual Screening and Biological Evaluation of Novel Low Molecular Weight Protein Tyrosine Phosphatase Inhibitor for the Treatment of Insulin Resistance.
Feng B; Dong X; Liu Z; Zhang J; Liu H; Xu Y
Drug Des Devel Ther; 2023; 17():1191-1201. PubMed ID: 37113468
[TBL] [Abstract][Full Text] [Related]
8. [Does inhibition of tyrosine phosphatase 1B protect from obesity and type 2 diabetes?].
Ukkola O; Santaniemi M
Duodecim; 2002; 118(18):1857-62. PubMed ID: 12422667
[No Abstract] [Full Text] [Related]
9. A diabetes switch?
Gibbs WW
Sci Am; 1999 Jun; 280(6):16. PubMed ID: 10349730
[No Abstract] [Full Text] [Related]
10. Recent advances in protein tyrosine phosphatase 1B inhibitors.
Taylor SD; Hill B
Expert Opin Investig Drugs; 2004 Mar; 13(3):199-214. PubMed ID: 15013940
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Harley EA; Levens N
Curr Opin Investig Drugs; 2003 Oct; 4(10):1179-89. PubMed ID: 14649209
[TBL] [Abstract][Full Text] [Related]
12. Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance.
Goldstein BJ
J Clin Endocrinol Metab; 2002 Jun; 87(6):2474-80. PubMed ID: 12050202
[No Abstract] [Full Text] [Related]
13. Deletion of low molecular weight protein tyrosine phosphatase (Acp1) protects against stress-induced cardiomyopathy.
Wade F; Quijada P; Al-Haffar KM; Awad SM; Kunhi M; Toko H; Marashly Q; Belhaj K; Zahid I; Al-Mohanna F; Stanford SM; Alvarez R; Liu Y; Colak D; Jordan MC; Roos KP; Assiri A; Al-Habeeb W; Sussman M; Bottini N; Poizat C
J Pathol; 2015 Dec; 237(4):482-94. PubMed ID: 26213100
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the Low Molecular Weight Protein Tyrosine Phosphatase (LMPTP) as a Potential Therapeutic Strategy for Hepatic Progenitor Cells Lipotoxicity-Short Communication.
Alicka M; Kornicka-Garbowska K; Roecken M; Marycz K
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771123
[TBL] [Abstract][Full Text] [Related]
15. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.
Barr AJ
Future Med Chem; 2010 Oct; 2(10):1563-76. PubMed ID: 21426149
[TBL] [Abstract][Full Text] [Related]
16. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery.
Zhang S; Zhang ZY
Drug Discov Today; 2007 May; 12(9-10):373-81. PubMed ID: 17467573
[TBL] [Abstract][Full Text] [Related]
17. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
Sasaoka T; Wada T; Tsuneki H
Pharmacol Ther; 2006 Dec; 112(3):799-809. PubMed ID: 16842857
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological activity and structure-activity relationships of new benzoic acid-based protein tyrosine phosphatase inhibitors endowed with insulinomimetic effects in mouse C2C12 skeletal muscle cells.
Ottanà R; Maccari R; Mortier J; Caselli A; Amuso S; Camici G; Rotondo A; Wolber G; Paoli P
Eur J Med Chem; 2014 Jan; 71():112-27. PubMed ID: 24287560
[TBL] [Abstract][Full Text] [Related]
19. The structural basis for the selectivity of benzotriazole inhibitors of PTP1B.
Scapin G; Patel SB; Becker JW; Wang Q; Desponts C; Waddleton D; Skorey K; Cromlish W; Bayly C; Therien M; Gauthier JY; Li CS; Lau CK; Ramachandran C; Kennedy BP; Asante-Appiah E
Biochemistry; 2003 Oct; 42(39):11451-9. PubMed ID: 14516196
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
